New Warrants & DLCs tracking BYD, Meituan, AliHealth & Ping An Health
Investors can now gain exposure to a wider range of Hong Kong stocks via SGX-listed Warrants and DLCs with recent new listings. Warrants and...
375 Views
iX Biopharma: Blazing New Trails in Healthcare
Dr Janakan Krishnarajah has never shied away from thinking – or dreaming – big. In fact, setting bold targets is par for the...
184 Views
SGX’s Three China-Focused ETFs Average 17% 1Y Total Return
SGX lists three China-focused ETFs that seek to replicate the total returns of major equity market indices in China. They are: Xtrackers MSCI...
219 Views
Biolidics, iX Biopharma & Hyphens Pharma Outpace Peers in 2020 YTD
Singapore’s most traded primary-listed stocks that represent medical equipment manufacturing, biotech and pharmaceuticals all generated gains...
168 Views
Meituan Dianping – Is a One Billion U.S. Dollar Impairment Forthcoming?
Since initiating coverage prior to Meituan Dianping's (3690 HK) IPO, we have been bearish with respect to both its valuation and its business...
1.2k Views